Table 2.
Vaccine efficacy and effectiveness (at least one dose) in women under 26 years old.
| Efficacy and Effectiveness | Vaccine Type | HPV Status at Enrolment | Vaccine Efficacy (95% CI) |
|---|---|---|---|
| Efficacy against HPV 16/18 infection [15,34,41,42] | Bivalent | Naive | 91–100% (64.6% to 86%; 94.2% to 100) |
| Irrespective | 76% (67% to 83%) |
||
| Persistent infection with HPV 16/18 (6 months) [15] | Naive | 90% (87% to 92%) |
|
| Irrespective | 56% (49% to 62%) |
||
| Persistent infection with HPV 16/18 (12 months) [43] | Irrespective | 97.7% (83.5% to 99.7%) |
|
| Persistent infection with HPV 31/33/45 (12 months) [43] | Irrespective | 61.8% (16.7% to 82.5%) |
|
| CIN2+ associated with HPV 16/18 [15,40,44] | Naive | 92.9–97.4% (79.9% to 88.0%; 98.3% to 99.6) |
|
| Irrespective | 54% (43% to 63%) |
||
| CIN3+ associated with HPV 16/18 [15,40,44] | Naive | 87.0–94.9% (54.9% to 73.7%; 97.7% to 99.4%) |
|
| Irrespective | 74% (55% to 91%) |
||
| Any CIN2+ irrespective of HPV type [40] | Naive | 70.2% (54.7% to 80.9%) |
|
| Any CIN3+ irrespective of HPV type [15] | Naive | 92% (77% to 97%) |
|
| Irrespective | 45% (29% to 57%) |
||
| Efficacy against external anogenital and vaginal lesions associated with HPV 6/11/16/18 [45] | Quadrivalent | Naive | 100% (94% to 100%) |
| Persistent infection with HPV 6/11/16/18 (6 months) [15] | Naive | 87% (63% to 95%) |
|
| CIN2+ associated with HPV 6/11/16/18 [15] | Naive | 99% (91% to 100%) |
|
| Irrespective | 50% (41% to 58%) |
||
| CIN3+ associated with HPV 6/11/16/18 [15] | Naive | 99% (82% to 100%) |
|
| Any CIN2+ irrespective of HPV type [15] | Naive | 43% (24% to 56%) |
|
| Any CIN3+ irrespective of HPV type [15] | Naive | 46% (17% to 64%) |
|
| Irrespective | 19% (4% to 31%) |
||
| Persistent infection with HPV 31/33/45/52/58 (≥6 months) [46,47] | Nonavalent | Naive (3 doses) |
95.2% (92.7% to 97.0%) |
| Irrespective | 95.8% (87.8% to 98.9%) | ||
| Persistent infection with HPV 31/33/45/52/58 (≥12 months) [46,48] | Naive (3 doses) |
96.3% (94.4% to 97.7%) | |
| Irrespective | 93.9% (81.4% to 98.4%) | ||
| CIN2/3, adenoma in situ, and cervical cancer associated with HPV 31/33/45/52/58 [47] | Naive (3 doses) |
90.9% (46.4% to 99.6%) | |
| Low-grade disease associated with HPV 31/33/45/52/58, including condyloma, CIN1, vulvar intraepithelial neoplasia 1, and vaginal intraepithelial neoplasia 1 [48] | Naive (3 doses) |
97.6% (91.7% to 99.6%) | |
| Irrespective | 84.0% (67.2% to 92.2%) | ||
| High-grade disease associated with HPV 31/33/45/52/58, including CIN2/3, adenoma in situ, cervical cancer, vulvar intraepithelial neoplasia 2/3, vulvar cancer, vaginal intraepithelial neoplasia 2/3, and vaginal cancer [48] | Naive (3 doses) |
96.7% (80.9% to 99.8%) | |
| Irrespective | 80.6% (33.7% to 94.3%) |